Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Point and Figure Charting -- Ignore unavailable to you. Want to Upgrade?

To: carl morgan who wrote (18939)	4/23/1999 2:31:00 PM
From: Ms. X	Read Replies (2) \| Respond to of 34811

Hi Carl, I like your 1/3rd plan. You could buy here and if this is the low and it reverses up, buy more then. Very good looking stock technically and fundamentally I believe. Wonder why it is down 7 today though? This of course doesn't look bad on the chart. 75 is a lovely entry. I do like the consolidation in the middle of the trading band. Jan I am

To: carl morgan who wrote (18939)	4/23/1999 2:55:00 PM
From: Les H	Respond to of 34811

Apparently, clarifications of the company's conference call the other day is causing the stock to give back its gains earlier this week according to Yahoo message board: I got a call from one of the brokers that covers our account, he said the $150M in Synvsic revenues from Wyeth is actually a decline from their last forecast of $180M, and that they are privately telling people $125M. He said that results in $50M in revenues for Biomatrix, which would be a shortfall. The most amazing part is that apparently while Biomatrix said that Wyeth's inventory was 23,000 kits, somehow the number got transposed and that it's actually 32,000 kits. I'm passing as unsubstantiated gossip since I have not verified anything with AHP other than the $150M number (since I was on that conference call). But it is consistent with my general thesis--that there is a slowing in enduser demand that will eventually show up in BXM's EPS, making the hockey-stick quarterly projections (Robby Stephens has $0.27, $.29, $.69,$.52 for this year) unachievable. Anyway, this is clearly what is moving the stock TODAY. Apparently anyone who was on the BXM conference call got a fax today about the mistake of the 32,000 kits in inventory rather than the 23,000. That works out to about $1.35M of BXM revenue in the quarter which went into Wyeth inventory rather than to enduser demand... ($50/syringe according to Pru Securities, x 9,000 x 3 vials/kit).